Their blood cancer drug failed also. If they aren'
Post# of 72440
Quote:
It’s not the first time Gilead has run into trial trouble. Earlier this year it halted 6 trials of its oncology med Zydelig (idelalisib) for first-line use in blood cancers after reports of serious side effects--including multiple deaths--among participants in several of the studies.